TY - JOUR
T1 - Transgenic α1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival
AU - Du, Xiao Jun
AU - Gao, Xiao Ming
AU - Kiriazis, Helen
AU - Moore, Xiao Lei
AU - Ming, Ziqiu
AU - Su, Yidan
AU - Finch, Angela M.
AU - Hannan, Ross A.
AU - Dart, Anthony M.
AU - Graham, Robert M.
PY - 2006/9/1
Y1 - 2006/9/1
N2 - Objective: Myocardial contractility is enhanced in transgenic (TG) mice with cardiac-restricted overexpression of the α1A-adrenergic receptors (α1A-AR). We tested the hypothesis that this enhanced inotropy protects against dysfunction and remodeling after myocardial infarction (MI). Methods: We subjected α1A-TG and non-TG mice (NTG) to MI and determined changes in left ventricular (LV) function and diastolic dimension (LVDd) by echocardiography prior to and at 1, 3, 7, 12 and 15 weeks thereafter. Results: Although infarct size was similar in the NTG and α1A-TG groups (32 ± 2 vs. 29 ± 2% of LV, P = NS), mortality due to heart failure was lower after MI in the α1A-TG (37%, n = 39) than that in the NTG animals (63%, n = 56, P = 0.026). NTG and α1A-TG mice showed similar reductions in LV fractional shortening (FS) and increases in LVDd at week-1 after MI. However, whereas NTG mice showed continuous deterioration over a 15-week period after MI in FS (fell by 40%, from 30 ± 2 to 18 ± 1%, P < 0.01) and LVDd (increased by 24%, from 4.2 ± 0.1 to 5.2 ± 0.1 mm, P < 0.01), the changes in both FS (fell by 14%, from 42 ± 2 to 36 ± 2%) and LVDd (increased by 8%, from 3.8 ± 0.1 to 4.1 ± 0.1 mm, both changes P < 0.01 vs. NTG) were significantly less severe in the α1A-TG mice and did not progress after 3 weeks. At 15 weeks after MI, LV catheterization revealed better preservation of dP/dtmax in the α1A-TG vs. NTG mice (7270 ± 324, vs. 5938 ± 372 mmHg/s, P < 0.05). Conclusion: Enhanced inotropy resulting from transgenic overexpression of α1A-AR is well maintained chronically after MI and limits echocardiography-determined LV remodeling, preserves function, and reduces acute heart failure death.
AB - Objective: Myocardial contractility is enhanced in transgenic (TG) mice with cardiac-restricted overexpression of the α1A-adrenergic receptors (α1A-AR). We tested the hypothesis that this enhanced inotropy protects against dysfunction and remodeling after myocardial infarction (MI). Methods: We subjected α1A-TG and non-TG mice (NTG) to MI and determined changes in left ventricular (LV) function and diastolic dimension (LVDd) by echocardiography prior to and at 1, 3, 7, 12 and 15 weeks thereafter. Results: Although infarct size was similar in the NTG and α1A-TG groups (32 ± 2 vs. 29 ± 2% of LV, P = NS), mortality due to heart failure was lower after MI in the α1A-TG (37%, n = 39) than that in the NTG animals (63%, n = 56, P = 0.026). NTG and α1A-TG mice showed similar reductions in LV fractional shortening (FS) and increases in LVDd at week-1 after MI. However, whereas NTG mice showed continuous deterioration over a 15-week period after MI in FS (fell by 40%, from 30 ± 2 to 18 ± 1%, P < 0.01) and LVDd (increased by 24%, from 4.2 ± 0.1 to 5.2 ± 0.1 mm, P < 0.01), the changes in both FS (fell by 14%, from 42 ± 2 to 36 ± 2%) and LVDd (increased by 8%, from 3.8 ± 0.1 to 4.1 ± 0.1 mm, both changes P < 0.01 vs. NTG) were significantly less severe in the α1A-TG mice and did not progress after 3 weeks. At 15 weeks after MI, LV catheterization revealed better preservation of dP/dtmax in the α1A-TG vs. NTG mice (7270 ± 324, vs. 5938 ± 372 mmHg/s, P < 0.05). Conclusion: Enhanced inotropy resulting from transgenic overexpression of α1A-AR is well maintained chronically after MI and limits echocardiography-determined LV remodeling, preserves function, and reduces acute heart failure death.
KW - α-adrenergic receptor
KW - Heart failure
KW - Ventricular remodeling
UR - http://www.scopus.com/inward/record.url?scp=33845186121&partnerID=8YFLogxK
U2 - 10.1016/j.cardiores.2006.06.015
DO - 10.1016/j.cardiores.2006.06.015
M3 - Article
C2 - 16859660
AN - SCOPUS:33845186121
SN - 0008-6363
VL - 71
SP - 735
EP - 743
JO - Cardiovascular Research
JF - Cardiovascular Research
IS - 4
ER -